CINECA IRIS Institutional Research Information System

IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.

Per chiedere supporto inviare una mail a: catalogo@unipr.it

Prodotti recenti

The fate of CdS Quantum Dots in plants as revealed by Extended X-ray Absorption Fine Structure (EXAFS) analysis

Use of Quantum Dots (QDs) is widespread and as such, the potential risk associated with their dispersion in the environment has stimulated research on interaction with potential sensitive receptors. To this end, the model plant Arabidopsis thaliana wild type (wt) and two mutant lin...

Recent insights into sodium and potassium handling by the aldosterone-sensitive distal nephron: implications on pathophysiology and drug discovery

As our understanding of the physiology of the aldosterone-sensitive distal nephron (ASDN) advanced in light of novel acquisitions, mainly pertaining the regulation of key ion channels and transporters by with-no-lysine kinases, the pathophysiology of a variety of conditions affecting this segment...

Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: A lust trial sub-project

Within the framework of the LUST trial (LUng water by Ultra-Sound guided Treatment to prevent death and cardiovascular events in high-risk end-stage renal disease patients), the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis ...

The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter

Mechanisms of resistance to target therapies in non-small cell lung cancer

Targeted therapies are revolutionizing the treatment of advanced non-small cell lung cancer (NSCLC). The discovery of key oncogenic events mainly in lung adenocarcinoma, like EGFR mutations or ALK rearrangements, has changed the treatment landscape while improving the prognosis of lung cancer...